Liver Failure/Cirrhosis/Portal Hypertension

You have full text access to this OnlineOpen article

L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure†‡

  1. Lars Marius Ytrebø1,§,*,
  2. Rune Gangsøy Kristiansen1,
  3. Hanne Mæhre2,
  4. Ole Martin Fuskevåg3,
  5. Trine Kalstad4,
  6. Arthur Revhaug4,
  7. María Jover Cobos5,
  8. Rajiv Jalan6,¶,*,
  9. Christopher F. Rose7,*

Article first published online: 18 FEB 2009

DOI: 10.1002/hep.22917

Issue

Hepatology

Hepatology

Volume 50, Issue 1, pages 165–174, July 2009

Additional Information

How to Cite

Ytrebø, L. M., Kristiansen, R. G., Mæhre, H., Fuskevåg, O. M., Kalstad, T., Revhaug, A., Cobos, M. J., Jalan, R. and Rose, C. F. (2009), L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure. Hepatology, 50: 165–174. doi: 10.1002/hep.22917

Author Information

  1. 1

    Department of Anesthesiology, University Hospital of North Norway and University of Tromsø, Norway

  2. 2

    Institute of Marine Biotechnology, University of Tromsø, Norway

  3. 3

    Department of Clinical Pharmacology, University Hospital of North Norway and University of Tromsø, Norway

  4. 4

    Department of Digestive Surgery, University Hospital of North Norway and University of Tromsø, Norway

  5. 5

    Unit for Clinical Management of Digestive Diseases-CIBERehd, Hospital Universitario de Valme, Seville, Spain

  6. 6

    Liver Failure Group, Institute of Hepatology, University College London Medical School, UK

  7. 7

    Neuroscience Research Unit, Hôpital Saint-Luc (CRCHUM), Université de Montréal, Québec, Canada

  1. §

    fax: +47 776 26192

  2. fax: +44 207 3800405

*Department of Anesthesiology, University Hospital of North Norway and University of Tromsø, N-9038 Tromsø, Norway

  1. †

    Potential conflict of interest: University College London has filed for patents surrounding the use of L-Ornithine and Phenylacetate/Phenylbutyrate for the treatment of hepatic encephalopathy, which has been licensed to Ocera Therapeutics.

  2. ‡

    See Editorial on Page 3

Publication History

  1. Issue published online: 23 JUN 2009
  2. Article first published online: 18 FEB 2009
  3. Accepted manuscript online: 18 FEB 2009 12:00AM EST
  4. Manuscript Accepted: 9 FEB 2009
  5. Manuscript Received: 6 MAY 2008

Funded by

  • Norwegian Research Council
  • Helse Nord
  • Fonds de Recherche en Santé du Quebec (FRSQ, Canada)
  • University College London Business

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (900K)

References

  • 1
    Lee WM, Squires RH Jr, Nyberg SL, Doo E, Hoofnagle JH. Acute liver failure: summary of a workshop. HEPATOLOGY 2008; 47: 1401–1415.
    Direct Link:
  • 2
    Jalan R, Olde Damink SW, Hayes PC, Deutz NE, Lee A. Pathogenesis of intracranial hypertension in acute liver failure: inflammation, ammonia and cerebral blood flow. J Hepatol 2004; 41: 613–620.
  • 3
    Clemmesen JO, Larsen FS, Kondrup J, Hansen BA, Ott P. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. HEPATOLOGY 1999; 29: 648–653.
    Direct Link:
  • 4
    Bernal W, Hall C, Karvellas CJ, Auzinger G, Sizer E, Wendon J. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. HEPATOLOGY 2007; 46: 1844–1852.
    Direct Link:
  • 5
    Bhatia V, Singh R, Acharya SK. Predictive value of arterial ammonia for complications and outcome in acute liver failure. Gut 2006; 55: 98–104.
  • 6
    Olde Damink SW, Deutz NE, Dejong CH, Soeters PB, Jalan R. Interorgan ammonia metabolism in liver failure. Neurochem Int 2002; 41: 177–188.
  • 7
    Olde Damink SW, Dejong CH, Deutz NE, Redhead DN, Hayes PC, Soeters PB, et al. Kidney plays a major role in ammonia homeostasis after portasystemic shunting in patients with cirrhosis. Am J Physiol Gastrointest Liver Physiol 2006; 291: G189–G194.
  • 8
    Olde Damink SW, Jalan R, Deutz NE, Redhead DN, Dejong CH, Hynd P, et al. The kidney plays a major role in the hyperammonemia seen after simulated or actual GI bleeding in patients with cirrhosis. HEPATOLOGY 2003; 37: 1277–1285.
    Direct Link:
  • 9
    Olde Damink SW, Jalan R, Redhead DN, Hayes PC, Deutz NE, Soeters PB. Interorgan ammonia and amino acid metabolism in metabolically stable patients with cirrhosis and a TIPSS. HEPATOLOGY 2002; 36: 1163–1171.
    Direct Link:
  • 10
    Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med 1997; 337: 473–479.
  • 11
    Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004; 328: 1046.
  • 12
    Festi D, Vestito A, Mazzella G, Roda E, Colecchia A. Management of hepatic encephalopathy: focus on antibiotic therapy. Digestion 2006; 73( Suppl 1): S94–S101.
  • 13
    Alba A, Haj J, Angulo P, Lee W. Lactulose therapy in acute liver failure. J Hepatol 2002; 36: 33.
  • 14
    Rose C, Michalak A, Rao KV, Quack G, Kircheis G, Butterworth RF. L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure. HEPATOLOGY 1999; 30: 636–640.
    Direct Link:
  • 15
    Jalan R, Wright G, Davies NA, Hodges SJ. L-Ornithine phenylacetate (OP): a novel treatment for hyperammonemia and hepatic encephalopathy. Med Hypotheses 2007; 69: 1064–1069.
  • 16
    Brusilow SW, Danney M, Waber LJ, Batshaw M, Burton B, Levitsky L, et al. Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. N Engl J Med 1984; 310: 1630–1634.
  • 17
    Smith I. The treatment of inborn errors of the urea cycle. Nature 1981; 291: 378–380.
  • 18
    Darmaun D, Welch S, Rini A, Sager BK, Altomare A, Haymond MW. Phenylbutyrate-induced glutamine depletion in humans: effect on leucine metabolism. Am J Physiol 1998; 274: E801–E807.
  • 19
    Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N Engl J Med 2007; 356: 2282–2292.
  • 20
    Ytrebo LM, Nedredal GI, Langbakk B, Revhaug A. An experimental large animal model for the assessment of bioartificial liver support systems in fulminant hepatic failure. Scand J Gastroenterol 2002; 37: 1077–1088.
  • 21
    Sen S, Rose C, Ytrebo LM, Davies NA, Nedredal GI, Drevland SS, et al. Effect of albumin dialysis on intracranial pressure increase in pigs with acute liver failure: a randomized study. Crit Care Med 2006; 34: 158–164.
  • 22
    Ytrebo LM, Korvald C, Nedredal GI, Elvenes OP, Nielsen Grymyr OJ, Revhaug A. N-acetylcysteine increases cerebral perfusion pressure in pigs with fulminant hepatic failure. Crit Care Med 2001; 29: 1989–1995.
  • 23
    Ytrebo LM, Ingebrigtsen T, Nedredal GI, Elvenes OP, Korvald C, Romner B, et al. Protein S-100beta: a biochemical marker for increased intracranial pressure in pigs with acute hepatic failure. Scand J Gastroenterol 2000; 35: 546–551.
  • 24
    Rose C, Ytrebo LM, Davies NA, Sen S, Nedredal GI, Belanger M, et al. Association of reduced extracellular brain ammonia, lactate, and intracranial pressure in pigs with acute liver failure. HEPATOLOGY 2007; 46: 1883–1892.
    Direct Link:
  • 25
    Dragnes BT, Larsen R, Ernsten MH, Maehre H, Elvevoll EO. Impact of processing on the taurine content in processed seafood and their corresponding unprocessed raw materials. Int J Food Sci Nutr 2008: 1–10.
  • 26
    Minet R, Villie F, Marcollet M, Meynial-Denis D, Cynober L. Measurement of glutamine synthetase activity in rat muscle by a colorimetric assay. Clin Chim Acta 1997; 268: 121–132.
  • 27
    Khan SA, Shah N, Williams R, Jalan R. Acute liver failure: a review. Clin Liver Dis 2006; 10: 239–258, vii–viii.
  • 28
    Cordoba J, Lopez-Hellin J, Planas M, Sabin P, Sanpedro F, Castro F, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol 2004; 41: 38–43.
  • 29
    Staedt U, Leweling H, Gladisch R, Kortsik C, Hagmuller E, Holm E. Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design. J Hepatol 1993; 19: 424–430
  • 30
    Rose C, Michalak A, Pannunzio P, Therrien G, Quack G, Kircheis G, et al. L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action. Metab Brain Dis 1998; 13: 147–157.
  • 31
    Ytrebo LM, Sen S, Rose C, Davies NA, Nedredal GI, Fuskevaag OM, et al. Systemic and regional hemodynamics in pigs with acute liver failure and the effect of albumin dialysis. Scand J Gastroenterol 2006; 41: 1350–1360.
  • 32
    Mignon M, Leveque L, Bonnel E, Meynial-Denis D. Does concomitant glucose and glutamine supplementation change the response of glutamine synthetase to fasting in healthy adult rats? Clin Nutr 2007; 26: 662–666.
  • 33
    Watford M, Darcy-Vrillon B, Duee PH. Dietary glutamine suppresses endogenous glutamine turnover in the rat. Metabolism 2000; 49: 141–145.
  • 34
    Smith RJ, Larson S, Stred SE, Durschlag RP. Regulation of glutamine synthetase and glutaminase activities in cultured skeletal muscle cells. J Cell Physiol 1984; 120: 197–203.
    Direct Link:
  • 35
    Kasumov T, Brunengraber LL, Comte B, Puchowicz MA, Jobbins K, Thomas K, et al. New secondary metabolites of phenylbutyrate in humans and rats. Drug Metab Dispos 2004; 32: 10–19.
  • 36
    Davies NA, Wright G, Ytrebø LM, Stadlbauer V, Ole-Martin F, Zwingman C, et al. L-Ornithine and phenylacetate synergistically produces sustained reduction in ammonia and brain water in cirrhotic rats. HEPATOLOGY 2009; 49(in press).
View Full Article with Supporting Information (HTML) Get PDF (900K)